STOCKHOLM--(BUSINESS WIRE)--Data show that treatment with a single-pill combination of telmisartan, an angiotensin receptor blocker, (ARB) and amlodipine, a calcium channel blocker (CCB) results in significant reductions in blood pressure (BP) in patients with severe hypertension.1 The data, which was presented recently at 20th Scientific Meeting of the European Society of Hypertension (ESH) in Oslo, and was discussed today at a briefing in Stockholm, also demonstrate the consistently higher BP control/response rates achieved compared to treatment with telmisartan or amlodipine treatment alone.
